The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) is a huge mover today! About 2.33 million shares traded hands or 13.66% up from the average. Dynavax Technologies Corporation (NASDAQ:DVAX) has declined 34.93% since February 29, 2016 and is downtrending. It has underperformed by 47.14% the S&P500.
The move comes after 5 months positive chart setup for the $496.01 million company. It was reported on Oct, 3 by Barchart.com. We have $35.02 PT which if reached, will make NASDAQ:DVAX worth $872.98M more.
Analysts await Dynavax Technologies Corporation (NASDAQ:DVAX) to report earnings on November, 3. They expect $-0.74 EPS, up 9.76% or $0.08 from last year’s $-0.82 per share. After $-0.75 actual EPS reported by Dynavax Technologies Corporation for the previous quarter, Wall Street now forecasts -1.33% EPS growth.
Dynavax Technologies Corporation (NASDAQ:DVAX) Ratings Coverage
Out of 2 analysts covering Dynavax Technologies (NASDAQ:DVAX), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Dynavax Technologies has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. JP Morgan downgraded it to “Neutral” rating and $22 target price in Wednesday, April 27 report. As per Wednesday, August 12, the company rating was upgraded by Zacks. The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) has “Sector Perform” rating given on Thursday, April 28 by RBC Capital Markets. The stock has “Outperform” rating given by RBC Capital Markets on Monday, November 30.
According to Zacks Investment Research, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.”
Insitutional Activity: The institutional sentiment decreased to 1.02 in Q2 2016. Its down 0.04, from 1.06 in 2016Q1. The ratio turned negative, as 18 funds sold all Dynavax Technologies Corporation shares owned while 34 reduced positions. 10 funds bought stakes while 43 increased positions. They now own 31.67 million shares or 4.27% less from 33.08 million shares in 2016Q1.
Reilly Fincl Advsr Limited Company has invested 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). Rhenman & Prns Asset Management last reported 0.39% of its portfolio in the stock. Panagora Asset Management Incorporated holds 0.02% or 340,600 shares in its portfolio. Blackrock Japan accumulated 2,875 shares or 0% of the stock. State Board Of Administration Of Florida Retirement holds 0% or 15,836 shares in its portfolio. Moreover, Teacher Retirement Systems Of Texas has 0% invested in Dynavax Technologies Corporation (NASDAQ:DVAX) for 5,064 shares. Federated Investors Inc Pa holds 0.13% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX) for 2.96 million shares. Howard Hughes Institute has 21,355 shares for 0.1% of their US portfolio. Metropolitan Life Ins Ny accumulated 28,014 shares or 0% of the stock. Millennium Mngmt holds 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX) for 84,506 shares. The New York-based Blackrock Incorporated has invested 0% in Dynavax Technologies Corporation (NASDAQ:DVAX). Putnam Invs Limited Liability Company holds 175,729 shares or 0.01% of its portfolio. Mutual Of America Cap Ltd Liability Corporation accumulated 0.01% or 21,900 shares. Commercial Bank Of New York Mellon holds 187,933 shares or 0% of its portfolio. Falcon Point, a California-based fund reported 21,753 shares.
Insider Transactions: Since May 12, 2016, the stock had 2 insider purchases, and 0 selling transactions for $57,940 net activity. Janssen Robert bought $15,120 worth of Dynavax Technologies Corporation (NASDAQ:DVAX) on Thursday, May 12. Shares for $42,820 were bought by Gray Eddie.
More news for Dynavax Technologies Corporation (NASDAQ:DVAX) were recently published by: Investorplace.com, which released: “Dynavax Technologies Corporation (DVAX) Injected With 20%-Plus Gains” on September 06, 2016. Prnewswire.com‘s article titled: “Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” and published on September 06, 2016 is yet another important article.
DVAX Company Profile
Dynavax Technologies Corporation (Dynavax), incorporated on November 6, 2000, is a clinical-stage biopharmaceutical company. The Firm uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. The Company’s development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). The Company’s lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. The Company’s SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. The Company’s advanced inflammatory disease candidate is AZD1419. The Company’s pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.